Ignite Creation Date:
2025-12-26 @ 12:16 PM
Ignite Modification Date:
2026-01-01 @ 5:59 AM
Study NCT ID:
NCT04934800
Status:
COMPLETED
Last Update Posted:
2025-06-24
First Post:
2021-06-17
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)
Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-12-10
Start Date Type:
ACTUAL
Primary Completion Date:
2024-05-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-05-20
Completion Date Type:
ACTUAL
First Submit Date:
2021-06-17
First Submit QC Date:
None
Study First Post Date:
2021-06-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-05-20
Results First Submit QC Date:
None
Results First Post Date:
2025-06-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-23
Last Update Post Date:
2025-06-24
Last Update Post Date Type:
ACTUAL